Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Board Changes

Tuesday, March 26, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has made significant strides in its clinical development, including the dosing of its first patient in a Phase 1/2a study for BetaBart (RV-01). Additionally, the company has received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments indicate progress in their research pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated clinical studies for BetaBart (RV-01).
  • The company received IND approval from the US FDA for its therapeutic study.

Full Press Release Details

• Announcements
• March 26, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• September 28, 2023
• Updates
• March 18, 2024
• Announcements
• March 31, 2022
• Announcements
• January 10, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent updates has Radiopharm Theranostics announced?

Radiopharm Theranostics has announced board changes and updates on clinical trials.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic agent being studied in clinical trials by Radiopharm.

What FDA approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA to initiate a Phase I study targeting B7H3.

When did Radiopharm dose its first patient?

Radiopharm Theranostics dosed its first patient in the Phase 1/2a clinical study of BetaBart.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart clinical trials FDA approval B7H3
Last updated: Mar 26, 2024